Riboflavin/UVA photochemical therapy for severe infectious keratitis

Alon Skaat*, David Zadok, Yakov Goldich, David Varssano, Yoav Berger, Orit Ezra-Nimni, Isaac Avni, Irina S. Barequet

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Purpose: To describe the antibacterial activity of treatment with riboflavin and ultraviolet A light (UVA) in cases of severe infectious keratitis. Methods: A retrospective analysis was performed of an interventional case series in which 6 eyes of 6 patients with severe infectious keratitis, all of whom were refractive to multidrug conventional therapy, were treated with riboflavin/UVA. The procedure was conducted according to the standardized protocol of corneal collagen crosslinking (CXL) for keratoconus. Best spectacle-corrected visual acuity and clinical outcomes were evaluated before and during the follow-up period. Results: Five of the 6 patients showed rapid reduction in symptoms and decreased infiltrate size after riboflavin/UVA photochemical therapy. Signs of infection and inflammation mostly resolved within 1 to 2 weeks after the treatment. Despite this therapy, one patient continued to deteriorate, and penetrating keratoplasty was performed. Conclusions: The adjunctive use of riboflavin/UVA photochemical therapy has a positive effect on refractory infectious keratitis. The treatment seems to be safe and effective and should be considered as part of the first-line therapy in severe cases of infectious keratitis.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalEuropean Journal of Ophthalmology
Volume24
Issue number1
DOIs
StatePublished - 17 Jul 2013

Keywords

  • Collagen crosslinking
  • Cornea
  • Infiltrate
  • Riboflavin
  • Ultraviolet A light

Fingerprint

Dive into the research topics of 'Riboflavin/UVA photochemical therapy for severe infectious keratitis'. Together they form a unique fingerprint.

Cite this